CD40L Antagonism in Rheumatoid Arthritis (RA)
| 适应症 | Rheumatoid Arthritis |
|---|---|
| 分期 | 2期 |
| 申办方 | National Institute of Allergy and Infectious Diseases (NIAID) |
| 状态 | 提前终止 |
| 受试者人数 | 2 人 |
| 干预（药物） | Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi |
| 开始日期 | 2023年7月25日 |
| 完成日期 | 2025年7月28日 |
| 结果公布日 | 2026年7月20日 |
摘要
The primary objective is to determine if the addition of a 12-week course of treatment with VIB4920 to TNFi treatment will result in improved clinical disease control in patients with RA who have had an inadequate response to a TNFi.
Proportion of Participants Achieving Low Disease Activity by Simplified Disease Activity Index (SDAI)
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- Dietary Salt in Rheumatoid Arthritis — Vanderbilt University Medical Center
- Feasibility and Acceptability of PREVAIL (PREserving Valued Activities In Life) — University of North Carolina, Chapel Hill
- Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With R — Alfasigma S.p.A.
- A Study of Baricitinib in Participants With Rheumatoid Arthritis — Eli Lilly and Company
- A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis — Eli Lilly and Company
- Long Term Follow-up of Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replace — Smith & Nephew, Inc.